Component

Zinc acetate

Zinc acetate; read each linked claim for the measured context and model.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Mean overall cold duration was 4.0 days with zinc versus 7.1 with placebo (P<.0001); cough lasted 2.1 versus 5.0 days and nasal discharge 3.0 versus 4.5 days.

    Zinc acetate → Common cold symptom duration source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Zinc exposure and the specifically measured response.
    evidence_location
    Indexed primary abstract.
    evidence_span
    {"source_cache": "artifacts/zinc-clinical-sources/prasad2008.abstract.txt", "locator": "Primary indexed abstract; complete local file", "file_sha256": "fbee9b28c3866295933e0baab1770cdaab0b62567ec2787a587522e493051b6e", "utf8_bytes": 1456}
    experimental_model
    Double-blind randomized placebo-controlled trial in 50 adults enrolled within 24 hours of cold onset
    exposure
    One lozenge with 13.3 mg elemental zinc as acetate every 2–3 hours while awake.
    limitations
    Small trial with subjective symptoms; biomarker differences do not prove the proposed antioxidant or anti-inflammatory pathway mediates benefit.
    nutrient_topic
    Zinc research collection; topical membership is not evidence of a direct dietary effect. · Zinc
    organism
    Homo sapiens
    plain_language
    This small acetate-lozenge trial found shorter symptoms.
    primary_references
    [zn-clin-prasad2008] Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. (2008). https://pubmed.ncbi.nlm.nih.gov/18279051/ DOI: 10.1086/528803
    tissue_or_cell_type
    Upper respiratory symptoms

    Zinc: transport, enzyme loading, deficiency and nutrient interactions (2026-09-17) · lines 1543–1556

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized placebo-controlled trial in 50 adults enrolled within 24 hours of cold onset · source_derived_draft · unverified_draft

    ### zn-clin-cold-duration-positive Mean overall cold duration was 4.0 days with zinc versus 7.1 with placebo (P<.0001); cough lasted 2.1 versus 5.0 days and nasal discharge 3.0 versus 4.5 days. Condition category: normal nutrient_topic: Zinc research collection; topical membership is not evidence of a direct dietary effect. plain_language: This small acetate-lozenge trial found shorter symptoms. organism: Homo sapiens tissue_or_cell_type: Upper respiratory symptoms experimental_model: Double-blind randomized placebo-controlled trial in 50 adults enrolled within 24 hours of cold onset limitations: Small trial with subjective symptoms; biomarker differences do not prove the proposed antioxidant or anti-inflammatory pathway mediates benefit. exposure: One lozenge with 13.3 mg elemental zinc as acetate every 2–3 hours while awake. cross_nutrient: Zinc exposure and the specifically measured response. evidence_location: Indexed primary abstract. evidence_span: {"source_cache": "artifacts/zinc-clinical-sources/prasad2008.abstract.txt", "locator": "Primary indexed abstract; complete local file", "file_sha256": "fbee9b28c3866295933e0baab1770cdaab0b62567ec2787a587522e493051b6e", "utf8_bytes": 1456} [zn-clin-prasad2008] Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. (2008). https://pubmed.ncbi.nlm.nih.gov/18279051/ DOI: 10.1086/528803
    Complete structured claim and evidence

  2. The tested commercial lozenge did not significantly improve ten-day recovery: zinc/placebo recovery-rate ratio .68 (95% CI .42–1.08; P=.10).

    Zinc acetate → Common cold recovery rate source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Zinc exposure and the specifically measured response.
    evidence_location
    Indexed primary abstract; accessible manuscript Methods and Results also inspected.
    evidence_span
    {"source_cache": "artifacts/zinc-clinical-sources/hemila2020.abstract.txt", "locator": "Primary indexed abstract; complete local file", "file_sha256": "581a713c4eeae243c2c96cb508cfe731318175d77c781476575775c09b6e9913", "utf8_bytes": 2004}
    experimental_model
    Double-blind randomized placebo-controlled Finnish trial: 253 packages allocated; 87 colds analyzed
    exposure
    Commercial acetate lozenges: 13 mg elemental zinc, six times daily, at most five days; nominal 78 mg/day.
    limitations
    This specific formulation dissolved in about eight minutes. Authors extended planned seven-day recovery analysis to ten days after finding no significant difference. Results do not identify why other formulations differ.
    nutrient_topic
    Zinc research collection; topical membership is not evidence of a direct dietary effect. · Zinc
    organism
    Homo sapiens
    plain_language
    A different acetate-lozenge regimen did not show faster recovery.
    primary_references
    [zn-clin-hemila2020] Zinc acetate lozenges for the treatment of the common cold: a randomised controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31980506/ DOI: 10.1136/bmjopen-2019-031662
    tissue_or_cell_type
    Upper respiratory symptoms and tolerability

    Zinc: transport, enzyme loading, deficiency and nutrient interactions (2026-09-17) · lines 1558–1571

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized placebo-controlled Finnish trial: 253 packages allocated; 87 colds analyzed · source_derived_draft · unverified_draft

    ### zn-clin-cold-recovery-null The tested commercial lozenge did not significantly improve ten-day recovery: zinc/placebo recovery-rate ratio .68 (95% CI .42–1.08; P=.10). Condition category: normal nutrient_topic: Zinc research collection; topical membership is not evidence of a direct dietary effect. plain_language: A different acetate-lozenge regimen did not show faster recovery. organism: Homo sapiens tissue_or_cell_type: Upper respiratory symptoms and tolerability experimental_model: Double-blind randomized placebo-controlled Finnish trial: 253 packages allocated; 87 colds analyzed limitations: This specific formulation dissolved in about eight minutes. Authors extended planned seven-day recovery analysis to ten days after finding no significant difference. Results do not identify why other formulations differ. exposure: Commercial acetate lozenges: 13 mg elemental zinc, six times daily, at most five days; nominal 78 mg/day. cross_nutrient: Zinc exposure and the specifically measured response. evidence_location: Indexed primary abstract; accessible manuscript Methods and Results also inspected. evidence_span: {"source_cache": "artifacts/zinc-clinical-sources/hemila2020.abstract.txt", "locator": "Primary indexed abstract; complete local file", "file_sha256": "581a713c4eeae243c2c96cb508cfe731318175d77c781476575775c09b6e9913", "utf8_bytes": 2004} [zn-clin-hemila2020] Zinc acetate lozenges for the treatment of the common cold: a randomised controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31980506/ DOI: 10.1136/bmjopen-2019-031662
    Complete structured claim and evidence

  3. No adverse effects were reported by 37% of zinc recipients compared with 69% of placebo recipients. Taste was a prominent tolerability issue.

    Zinc acetate → Adverse effects during zinc lozenge use source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Zinc exposure and the specifically measured response.
    evidence_location
    Indexed primary abstract; accessible manuscript Methods and Results also inspected.
    evidence_span
    {"source_cache": "artifacts/zinc-clinical-sources/hemila2020.abstract.txt", "locator": "Primary indexed abstract; complete local file", "file_sha256": "581a713c4eeae243c2c96cb508cfe731318175d77c781476575775c09b6e9913", "utf8_bytes": 2004}
    experimental_model
    Double-blind randomized placebo-controlled Finnish trial: 253 packages allocated; 87 colds analyzed
    exposure
    Commercial acetate lozenges: 13 mg elemental zinc, six times daily, at most five days; nominal 78 mg/day.
    limitations
    This specific formulation dissolved in about eight minutes. Authors extended planned seven-day recovery analysis to ten days after finding no significant difference. Results do not identify why other formulations differ.
    nutrient_topic
    Zinc research collection; topical membership is not evidence of a direct dietary effect. · Zinc
    organism
    Homo sapiens
    plain_language
    The zinc lozenge caused more reported side effects.
    primary_references
    [zn-clin-hemila2020] Zinc acetate lozenges for the treatment of the common cold: a randomised controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31980506/ DOI: 10.1136/bmjopen-2019-031662
    tissue_or_cell_type
    Upper respiratory symptoms and tolerability

    Zinc: transport, enzyme loading, deficiency and nutrient interactions (2026-09-17) · lines 1573–1586

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized placebo-controlled Finnish trial: 253 packages allocated; 87 colds analyzed · source_derived_draft · unverified_draft

    ### zn-clin-cold-tolerability No adverse effects were reported by 37% of zinc recipients compared with 69% of placebo recipients. Taste was a prominent tolerability issue. Condition category: normal nutrient_topic: Zinc research collection; topical membership is not evidence of a direct dietary effect. plain_language: The zinc lozenge caused more reported side effects. organism: Homo sapiens tissue_or_cell_type: Upper respiratory symptoms and tolerability experimental_model: Double-blind randomized placebo-controlled Finnish trial: 253 packages allocated; 87 colds analyzed limitations: This specific formulation dissolved in about eight minutes. Authors extended planned seven-day recovery analysis to ten days after finding no significant difference. Results do not identify why other formulations differ. exposure: Commercial acetate lozenges: 13 mg elemental zinc, six times daily, at most five days; nominal 78 mg/day. cross_nutrient: Zinc exposure and the specifically measured response. evidence_location: Indexed primary abstract; accessible manuscript Methods and Results also inspected. evidence_span: {"source_cache": "artifacts/zinc-clinical-sources/hemila2020.abstract.txt", "locator": "Primary indexed abstract; complete local file", "file_sha256": "581a713c4eeae243c2c96cb508cfe731318175d77c781476575775c09b6e9913", "utf8_bytes": 2004} [zn-clin-hemila2020] Zinc acetate lozenges for the treatment of the common cold: a randomised controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31980506/ DOI: 10.1136/bmjopen-2019-031662
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards